Literature DB >> 2112493

The management of predicted ovarian hyperstimulation involving gonadotropin-releasing hormone analog with elective cryopreservation of all pre-embryos.

N N Amso1, K K Ahuja, N Morris, R W Shaw.   

Abstract

Severe ovarian hyperstimulation syndrome complicates up to 6% of IVF treatment cycles. We have utilized our pre-embryo cryopreservation program to manage incipient ovarian hyperstimulation syndrome in an alternative way. Four women, who were at risk of developing ovarian hyperstimulation syndrome, underwent oocyte retrieval, but not embryo replacement. Instead, resulting pre-embryos were cryopreserved for future transfer. The four patients have since become pregnant. Three conceived after thawed embryo replacement cycles, and the fourth conceived spontaneously 1 month after the stimulation cycle. This approach offers maximum flexibility in the management of ovarian hyperstimulation syndrome.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2112493     DOI: 10.1016/s0015-0282(16)53591-2

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  16 in total

1.  Successful management of predicted severe ovarian hyperstimulation syndrome with gonadotropin-releasing hormone agonist.

Authors:  T C Wu; T J Gelety; M H Jih; N Fournet; R Buyalos
Journal:  J Assist Reprod Genet       Date:  1992-06       Impact factor: 3.412

2.  Prevention of ovarian hyperstimulation syndrome by early aspiration of small follicles in hyper-responsive patients with polycystic ovaries during assisted reproductive treatment cycles.

Authors:  Oluseye A Oyawoye; Bina Chander; Jocelyn Hunter; Ahmed Abdel Gadir
Journal:  MedGenMed       Date:  2005-08-16

3.  In vitro fertilization programmed for weekday-only oocyte harvest: analysis of outcome based on actual retrieval day.

Authors:  A Ben-Chetrit; S Senoz; E M Greenblatt
Journal:  J Assist Reprod Genet       Date:  1997-01       Impact factor: 3.412

4.  Elective preembryo cryopreservation in ovarian hyperstimulation syndrome.

Authors:  N N Amso; K K Ahuja; N Morris; R W Shaw
Journal:  J In Vitro Fert Embryo Transf       Date:  1989-10

5.  Outcome of frozen embryo replacement cycles following elective cryopreservation of all embryos in women at risk of developing ovarian hyperstimulation syndrome.

Authors:  A O Awonuga; N Dean; J Zaidi; R U Pittrof; J S Bekir; S L Tan
Journal:  J Assist Reprod Genet       Date:  1996-04       Impact factor: 3.412

Review 6.  Safety of drugs used in assisted reproduction techniques.

Authors:  Talha Al-Shawaf; Ariel Zosmer; Martha Dirnfeld; Gedis Grudzinskas
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

7.  Cumulative birth rates following cryopreservation of all embryos in stimulated in vitro fertilization (IVF) cycles.

Authors:  C Bergh; C Werner; L Nilsson; L Hamberger
Journal:  J Assist Reprod Genet       Date:  1995-03       Impact factor: 3.412

8.  The reproductive outcome following a superhigh response to stimulation in gamete intrafallopian transfer program.

Authors:  T al-Shawaf; A Nolan; P Nadkarni; J Harper; J Brown; R Guirgis; G Emerson; M Bayly; I Craft
Journal:  J In Vitro Fert Embryo Transf       Date:  1991-08

9.  The influence of supraphysiologic estradiol levels on human nidation.

Authors:  T J Gelety; R P Buyalos
Journal:  J Assist Reprod Genet       Date:  1995-08       Impact factor: 3.412

10.  Use of buserelin and low-dose human menopausal gonadotropin for in vitro fertilization in women at risk of ovarian hyperstimulation syndrome.

Authors:  I Wada; P L Matson; S A Troup; B A Lieberman
Journal:  J Assist Reprod Genet       Date:  1995-04       Impact factor: 3.412

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.